Clinical trial NCT04385810: Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19
Official title: Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Covid19
Sars-CoV2
Keywords: ophthalmological lesions
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2020-05-13
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The management of patients with SARS-CoV2 in respiratory distress can expose to corneal or retinal lesions induced by the stay in intensive care.

Examination by ophthalmologists would make it possible to detect the most of the ophthalmologic problems known in intensive care and to provide an early, preventive or curative therapeutic response when possible, in order to avoid irreversible visual loss.

The object of the research is to assess the presence and the importance of surface ophthalmologic lesions, the presence and the importance of retinal or optic nerve lesions, in order to improve the monitoring and primary prevention of this population


Eligibility criteria: Inclusion Criteria:

* patient SARS-CoV2 positive (RT-PCR or chest scanner)
* hospitalized in intensive care

Exclusion Criteria:

* traumatic lesion of the face or any other condition preventing any ophthalmological evaluation

Primary outcomes:
measure: Describe ophthalmologic damage to the cornea with direct exam at day 0
timeFrame: Day 0
measure: Describe ophthalmologic damage to the cornea with direct exam at day 7
timeFrame: Day 7
measure: Describe ophthalmologic damage to the cornea with direct exam at day 14
timeFrame: Day 14
measure: Describe ophthalmologic damage to the cornea with direct exam at discharge of hospital
timeFrame: Discharge of hospital, up to 3 months
measure: Describe ophthalmologic damage to the cornea with slit lamp exam at day 0
timeFrame: Day 0
measure: Describe ophthalmologic damage to the cornea with slit lamp exam at day 7
timeFrame: Day 7
measure: Describe ophthalmologic damage to the cornea with slit lamp exam at day 14
timeFrame: Day 14
measure: Describe ophthalmologic damage to the cornea with slit lamp exam at discharge of hospital
timeFrame: Discharge of hospital, up to 3 months
measure: Describe tear film anomalies at day 0
timeFrame: Day 0
measure: Describe tear film anomalies at day 7
timeFrame: Day 7
measure: Describe tear film anomalies at day 14
timeFrame: Day 14
measure: Describe tear film anomalies at discharge of hospital
timeFrame: Discharge of hospital, up to 3 months
measure: Describe ophthalmologic damage to the retina at day 0
timeFrame: Day 0
measure: Describe ophthalmologic damage to the retina at day 7
timeFrame: Day 7
measure: Describe ophthalmologic damage to the retina at day 14
timeFrame: Day 14
measure: Describe ophthalmologic damage to the retina at discharge of hospital
timeFrame: Discharge of hospital, up to 3 months
measure: Describe ophthalmologic damage to the optic nerve at day 0
timeFrame: Day 0
measure: Describe ophthalmologic damage to the optic nerve at day 7
timeFrame: Day 7
measure: Describe ophthalmologic damage to the optic nerve at day 14
timeFrame: Day 14
measure: Describe ophthalmologic damage to the optic nerve at discharge of hospital
timeFrame: Discharge of hospital, up to 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation Adolphe de Rothschild
Study officials:
affiliation: Fondation Adolphe de Rothschild
name: Jean Michel DEVYS, MD
role: PRINCIPAL_INVESTIGATOR
References: